Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study

This post-market study follows patients who received (or will receive) the Ankura aortic stent graft — a device implanted inside the thoracic aorta to treat a thoracic aortic aneurysm (a dangerous bulge in the main chest artery) or type B aortic dissection (a tear in the artery wall). The study tracks safety and performance over 3 years after implantation. You may be eligible if... - You are 18 to 85 years old - You have a descending thoracic aortic aneurysm or type B aortic dissection requiring endovascular repair - Your life expectancy exceeds 1 year - You have appropriate anatomy for the Ankura device per manufacturer guidelines - You are willing to attend follow-up visits for 3 years You may NOT be eligible if... - You have a genetic connective tissue disease such as Marfan syndrome or Ehlers-Danlos syndrome - You have had a heart attack or stroke within the past 3 months - You have severe heart failure (NYHA class 3–4) or unstable angina - You are pregnant or planning to become pregnant - You are severely obese (over 150 kg) - You have an active systemic infection Talk to your doctor to see if this trial is right for you.